Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13165978 | 0.84 | GSR (0.67) | GSRPTGS2SMN1; SMN2L3MBTL1MMP2 | |
| SCHEMBL13861088 | 0.83 | MAPT (0.52) | MAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL5058142 | 0.83 | GSR (0.61) | GSRPTGS2MMP2MMP9MMP8 | |
| SCHEMBL8051337 | 0.82 | SMN1; SMN2 (0.70) | MAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL12049935 | 0.82 | SMN1; SMN2 (0.50) | GSRMAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL15556865 | 0.82 | GSR (0.59) | GSRPTGS2MMP2MMP9MMP8 | |
| SCHEMBL7603248 | 0.82 | MAPT (0.50) | GSRMAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL22584909 | 0.82 | GSR (0.59) | GSRPTGS2MMP2MMP9MMP8 | |
| SCHEMBL16923800 | 0.82 | GSR (0.59) | GSRPTGS2MMP2MMP9MMP8 | |
| SCHEMBL125350 | 0.82 | GSR (0.59) | GSRMMP2MMP9MMP8ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200335181-A1 | DIGITAL REACTIONWARE | CHEMIFY LIMITED (GB) | 2020-10-22 | — | — | US | disclosed |
| CN-109415359-A | heterocyclic GPR119 agonist compounds | 人类制药有限公司 | 2019-03-01 | — | — | CN | disclosed |
| CN-104961674-B | Preparation method for the reference substance for synthesizing Etoricoxib | 湖南方盛制药股份有限公司 | 2018-08-17 | — | — | CN | disclosed |
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2018-03-08 | — | — | US | disclosed |
| US-9545449-B2 | Site-specific labeling and targeted delivery of proteins for the treatment of cancer | Advanced Proteone Therapeutics Inc. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20150202314-A1 | SITE-SPECIFIC LABELING AND TARGETED DELIVERY OF PROTEINS FOR THE TREATMENT OF CANCER | ADVANCED PROTEOME THERAPEUTICS INC. | 2015-07-23 | — | — | US | disclosed |
| US-20130296551-A1 | 7-MEMBERED RING COMPOUND AND METHOD OF PRODUCTION AND PHARMACEUTICAL APPLICATION THEREOF | DAIICHI SANKYO CO LTD (JP) | 2013-11-07 | — | — | US | disclosed |
| EP-2463268-B1 | 4-(Aminomethyl)benzoic acids as intermediates for the preparation of chymase inhibiting 1,4-diazepan-2,5-dione compounds | DAIICHI SANKYO CO LTD (JP) | 2013-08-28 | — | — | EP | disclosed |
| US-8507714-B2 | 7-membered ring compound and method of production and pharmaceutical application thereof | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-08-13 | — | — | US | disclosed |
| US-20130196978-A1 | ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-08-01 | — | — | US | disclosed |
| US-5981576-A | (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors | MERCK FROSST CANADA, INC. (CA) | 1999-11-09 | — | — | US | disclosed |
| US-5925631-A | NOVEL PRODRUGS ARE CONVERTED IN VIVO TO SELECTIVE CYCLOOXYGENASE-2 INHIBITORS; NONSTEROIDAL ANTIINFLAMMATORY AGENTS; SIDE EFFECT REDUCTION | MERCK & CO., INC. (US) | 1999-07-20 | — | — | US | disclosed |
| WO-1999018093-A1 | NOVEL 3,4-DIARYLTHIAZOLIN-2-ONE OR -2-THIONE DERIVATIVES, PREPARATION METHODS AND USES IN THERAPY | LABORATOIRES UPSA (FR) | 1999-04-15 | — | — | WO | disclosed |
| EP-0904269-A1 | 3,4-DIARYL-2-HYDROXY-2,5-DIHYDROFURANS AS PRODRUGS TO COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1999-03-31 | — | — | EP | disclosed |
| EP-0863891-A1 | (METHYLSULFONYL)PHENYL-2-(5H)-FURANONES AS COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1998-09-16 | — | — | EP | disclosed |
| US-5789413-A | ANTIINFLAMMATORY AGENT | MERCK FROSST CANADA, INC. (CA) | 1998-08-04 | — | — | US | disclosed |
| US-5698584-A | NON-STEROIDAL ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA, INC. (CA) | 1997-12-16 | — | — | US | disclosed |
| WO-1997016435-A1 | 3,4-DIARYL-2-HYDROXY-2,5-DIHYDROFURANS AS PRODRUGS TO COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1997-05-09 | — | — | WO | disclosed |
| WO-1997014691-A1 | (METHYLSULFONYL)PHENYL-2-(5H)-FURANONES AS COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1997-04-24 | — | — | WO | disclosed |
| US-4237141-A | BRONCHODILATORS | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1980-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150202314-A1 | SITE-SPECIFIC LABELING AND TARGETED DELIVERY OF PROTEINS FOR THE TREATMENT OF CANCER | KDR, VCAM1, FLT4 | GSR 3912/4885PTGS2 1209/4885MAPT 3401/4885 |
| US-20130196978-A1 | ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | CHRM3, CHRM1, CHRNG | GSR 2502/4885PTGS2 791/4885MAPT 1455/4885 |
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | CCNO, PTGDR, CCNE1 | GSR 308/4885PTGS2 51/4885MAPT 4552/4885 |
| US-20130296551-A1 | 7-MEMBERED RING COMPOUND AND METHOD OF PRODUCTION AND PHARMACEUTICAL APPLICATION THEREOF | CMA1, CPA3, SI | GSR 4227/4885PTGS2 1370/4885MAPT 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.